HDAC inhibitor REC-2282

Drug Overview

The HDAC inhibitor REC-2282 (also known as MGCD0103 or Mocetinostat) is an investigational, orally bioavailable small molecule designed to treat specific types of cancer and genetic disorders. It belongs to a class of drugs called histone deacetylase (HDAC) inhibitors, which work by modifying the epigenetic “switches” that control gene expression.

REC-2282 is a selective inhibitor of Class I and Class IV HDAC enzymes. It is currently being prioritized for the treatment of Neurofibromatosis Type 2 (NF2)-associated tumors, such as meningiomas, where it aims to restore the natural tumor-suppressive environment that the disease has disrupted.

• Generic Name: REC-2282 (Mocetinostat).
• Drug Class: Selective Histone Deacetylase (HDAC) Inhibitor / Epigenetic Modifier.
• Target: HDAC Class I (HDAC 1, 2, 3) and Class IV (HDAC 11).
• Route of Administration: Oral (Capsule).
• FDA Approval Status: Investigational. As of March 2026, REC-2282 is not FDA-approved. It has received Orphan Drug Designation and Fast Track Designation for NF2-mutated meningiomas. It is currently the subject of the pivotal Phase II/III POPLAR study.

What Is It and How Does It Work? (Mechanism of Action)

REC-2282 works by altering the structural “packaging” of DNA to reactivate genes that the cancer has forced into a dormant state.

Epigenetic Regulation and HDACs

In every cell, DNA is wrapped around proteins called histones. For a gene to be “turned on,” the histones must be acetylated (have an acetyl group attached), which loosens the DNA. HDAC enzymes act as “erasers,” removing these acetyl groups and causing the DNA to wrap tightly, which “silences” the gene. In NF2-related tumors, the loss of the Merlin protein leads to an overactivity of HDACs, which shuts down vital tumor-suppressor genes.

Molecular Level Mechanisms

1. Selective Enzyme Blockade: REC-2282 binds to the active site of Class I HDACs. Unlike “pan-HDAC” inhibitors that hit all enzymes, REC-2282 is more selective, which is intended to reduce toxicity while maintaining efficacy.
2. Hyperacetylation: By blocking the “eraser” enzymes, REC-2282 allows acetyl groups to accumulate on the histones.
3. Chromatin Opening: The accumulating acetyl groups create a negative charge that repels the DNA, causing the “packaging” to open up.
4. Reactivation of Tumor Suppressors: This open structure allows the cell’s machinery to access and reactivate genes like p21, which forces the tumor cell to stop dividing or undergo apoptosis (programmed cell death).
5. Microenvironment Modulation: In NF2 patients, REC-2282 may also reduce the inflammation and growth signaling within the “niche” where meningiomas grow.

FDA-Approved Clinical Indications

There are currently no FDA-approved indications for REC-2282.

Current clinical research is focused on:

• NF2-associated Meningiomas: For patients with the NF2 genetic mutation whose brain or spinal tumors are growing and for whom surgery or radiation is no longer an option.
• Non-Small Cell Lung Cancer (NSCLC): Previously studied in combination with other therapies to overcome resistance.
• Hematologic Malignancies: Historically investigated for Hodgkin Lymphoma and certain leukemias.

Dosage and Administration Protocols

As an investigational agent, REC-2282 is administered according to strict protocols in clinical trials to ensure patient safety.

Clinical Efficacy and Research Results

As of early 2026, data from the POPLAR trial (NCT05130866) and earlier studies have provided insights into the potential of REC-2282.

• Tumor Stability: Early results in NF2-mutated meningiomas have shown that REC-2282 can lead to “Stable Disease” in patients who previously had rapidly progressing tumors.
• Target Engagement: Biopsy data has confirmed that the drug successfully increases histone acetylation in human patients, proving the “epigenetic switch” is being flipped.
• Combinatorial Synergy: In lung cancer research, REC-2282 showed the ability to re-sensitize tumors to PD-1 inhibitors, suggesting it may have a future role as an “immuno-primer.”

Safety Profile and Side Effects

Because HDAC inhibitors affect gene expression systemically, they carry a specific profile of side effects, primarily affecting the blood and digestive system.

Common Side Effects (>20%):

• Gastrointestinal Distress: Nausea, vomiting, and diarrhea.
• Fatigue: A very common systemic effect of epigenetic modifiers.
• Anorexia: Decreased appetite and weight loss.
• Myelosuppression: A drop in white blood cell (neutropenia) and platelet (thrombocytopenia) counts.

Serious Risks:

• Cardiotoxicity: Like other drugs in this class, REC-2282 can potentially cause QT prolongation (a change in the heart’s electrical rhythm). Patients require regular EKGs.
• Pericardial Effusion: A rare but serious potential side effect where fluid builds up around the heart, which was noted in earlier high-dose trials of Mocetinostat.

Research Areas

In the fields of Stem Cell and Regenerative Medicine, REC-2282 is an important tool for studying “Cellular Plasticity.” Because HDAC inhibitors can “un-silence” genes, researchers use REC-2282 to investigate how to revert specialized cells back into a stem-like state. This research is vital for understanding how the body might “regenerate” healthy brain tissue after a tumor has been treated, or how to “re-program” the cells in the NF2 niche to stop forming tumors.

Patient Management and Practical Recommendations

Pre-treatment Tests:

• Genetic Testing: To confirm the presence of an NF2 mutation.
• Baseline EKG: To establish heart rhythm before starting therapy.
• Complete Blood Count (CBC): To ensure adequate bone marrow function.

Precautions:

• Heart Monitoring: Report any fainting, dizziness, or palpitations immediately.
• Infection Risk: Avoid close contact with sick individuals if white blood cell counts are low.

“Do’s and Don’ts” List:

• DO take the medication exactly as prescribed; the intermittent schedule (e.g., 3x a week) is critical for safety.
• DO stay well-hydrated to help your body manage potential gastrointestinal side effects.
• DON’T ignore a fever over 100.4°F (38°C), as this could be a sign of a serious infection while on treatment.
• DON’T take any new supplements or “natural” remedies without consulting your oncologist, as they may interfere with the drug’s metabolism.

Legal Disclaimer

The information provided is for educational purposes only and does not constitute medical advice. REC-2282 is an investigational agent and is not currently approved by the US FDA for any indication. It is available only through participation in approved clinical trials. Always consult with a qualified neuro-oncologist or hematologist-oncologist regarding your diagnosis and treatment options.